INTRODUCTION
Lung cancer is the leading cause of cancer related deaths worldwide (1) . It is estimated that 215,000 new cases will be 
The Evolution of Combined Modality Therapy
During the 1990's a shift occurred in the treatment of locally advanced NSCLC from radiotherapy alone to concurrent chemoradiation. A number of randomized phase II/III trials each played a role in the evolution of therapy to the current standard of concurrent chemoradiation. The process began with the development of sequential chemotherapy followed by radiation therapy.
Sequential Chemotherapy
A series of clinical trials investigating the use of sequential chemotherapy and radiation therapy were performed in the mid to late 1980's. The rationale of these trials was based on the premise that full doses of chemotherapy and radiation therapy could successfully be administered sequentially. They hypothesized that the chemotherapy would act to eliminate undetectable systemic micrometastatic disease while radiation therapy would act as a potent local treatment.
The Cancer and Leukemia Group B (CALGB) 8433 trial, also sometimes referred to as the Dillman trial, is notable for being an early trial that established the importance of the addition of chemotherapy in locally advanced NSCLC. The trial enrolled 155 patients with clinical stage III NSCLC. Patients were randomized to receive induction chemotherapy with cisplatin/vinblastine or no induction chemotherapy (2, 3) . All patients were also treated with conventionally fractionated radiation therapy to a total dose of 60 Gy. Analysis of the study showed a statistically significant improvement in the median survival of 13.7 months over 9.6 months (p=0.012) with sequential chemoradiation over radiation alone. The 5 year survival rate tripled with combined modality therapy over radiation alone (17% vs. 6%). It is also important to note that the sequential treatment regimen was not associated with an increase in clinically significant toxicity. (Table 1) . However, after the completion of these trials, questions still remained regarding the optimal timing of chemotherapy in combination with radiation therapy.
Concurrent Chemotherapy and Radiation Therapy
Despite the therapeutic improvement that was observed with RT: radiotherapy, CT: chemotherapy, n.r.: not reported, qd: daily, bid: twice daily, cddp: cisplatin, VCPC: vindesine, cyclophosphamide, cisplatin, and lomustine, Pts: number of patients the addition of induction chemotherapy, the prognosis of locally advanced NSCLC remained relatively poor. This was due to both continued problems with distant recurrence and also poor local control. In an effort to improve local control, trials were 8.9%), and response rate (84% vs. 66%). Interestingly, the trial seemed to support the hypothesis that local control could be improved by concurrent therapy. In the concurrent arm local-failure free survival was significantly greater (30 vs. 11 months) while the rate of distant failure was similar between both arms. This result was achieved in the context of split course radiation therapy, which is now widely considered to be an inferior approach. The only significance in toxicity between the two arms was an increase in myelosuppression in the concurrent arm.
The RTOG 9410 was a phase III randomized trial of 610 patients with unresectable stages II/III NSCLC (8, 9) . The trial was designed to investigate both a possible benefit of concurrent therapy and hyperfractionation. Patients were randomized to three arms: sequential chemotherapy and daily radiation, concurrent chemotherapy and daily radiation, or twice-daily radiation treatments. There was a statistically significant improvement in median survival (17.0 vs. 14.6 months; p=0.0038) and 4 year survival rate (21% vs. 12%; p=0.046) in the concurrent daily arm over the sequential arm. It was also significantly better than the twice-daily treatment arm. Acute toxicity rated grade 3 or higher was increased in the concurrent daily arm over that of the sequential arm (55% vs. 35%).
Another significant study was performed in the Czech Republic by Zatloukal et al. The trial included 102 patients who were randomized to cisplatin/vinorelbine given either as induction to or concurrent with 60 Gy (10). The study revealed that concurrent therapy resulted in significant improvement in median survival (16.6 vs. 12.9 months) and time to progression (11.9 vs. 8.5 months). There was also a significant improvement in overall response rate of 80% vs. 47% with the concurrent approach. Consistent with other studies, there was increased toxicity associated with the concurrent arm. Specifically, there were increases in leukopenia (53% vs. 19%), nau- The results of these studies provide compelling evidence that an approach using concurrent chemoradiation results in superior clinical outcome when compared to sequential therapy (Table   2 ). This improvement is associated with an increase in local control thought to result from radiosensitization. However, it is important to note that this improvement in local control comes at the cost of increased toxicity. Each of these randomized trials consistently demonstrated that more acute toxicity occurs when concurrent therapy is administered. These trials established concurrent chemoradiation as standard of care, but with time the role of chemotherapy has been further defined.
Concurrent Chemoradiation with Induction or Consolidation
Sequential chemoradiation improved clinical outcomes by providing better systemic control, while concurrent chemoradiation seems to improve locoregional control. A logical hypothesis is that combining both of these approaches could improve efficacy through better local and systemic control. However, the trial is significant because it compares induction chemotherapy to consolidation chemotherapy in the setting of concurrent chemoradiation. At a median follow-up of 39.6 months, the median overall survival was 13.0, 12.7, and 16.3 months, respectively, favoring the concurrent/consolidation arm.
It is important to note that there was increased toxicity in the concurrent/consolidation arm. Despite this, the authors concluded that the concurrent/consolidation arm had superior clinical outcomes.
Though there is no phase III data addressing the question of consolidation chemotherapy, the SWOG 9504 (13, 14) and LAMP (15) With a median follow-up of 28 months, the median survival time was 37 months.
The University of North Carolina investigators reported a phase I/II study that escalated radiation dose to 74 Gy from a starting dose of 60 Gy (21, 22) . Chemotherapy consisted of induction carboplatin and paclitaxel and, in contrast to other studies it was administered as induction for two cycles followed by concurrent chemoradiation with the same agents. Modern 3-D planning was used to escalate to the following doses: 60
Gy, 66 Gy, 70 Gy, and 74 Gy. With a median follow-up of 43 months, the median survival was 24 months. The overall survival rate was 50% at two years and 38% at three years.
Based on this study, 74 Gy was judged to be safe in the setting of concurrent chemotherapy consistent with other trials. 
